Secondly, only clinically stable T2-high severe asthma patients free of systemic steroids for at least 1 month before the study were considered; therefore, it remains unclear whether systemic glucocorticoids can affect the level of type 2 inflammatory mediators during treatment with anti-IL-5 mepolizumab. Here, IL5 is linked to asthma.